BRAF Targeted Therapy after Immunotherapy for Patients with Metastatic Melanoma: A Review of Clinical Effectiveness


( Last Updated : October 18, 2017)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0935-000

Details


Question


  1. What is the clinical effectiveness of BRAF targeted therapy in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy as their first-line option?


Key Message

Three non-randomized studies were identified regarding the clinical effectiveness of BRAF inhibitor targeted therapy in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy as their first-line option. Two of the studies were more favourable to treating with immunotherapy prior to BRAF inhibitor in patients with BRAF mutation positive melanoma. One study reported that the optimal sequencing paradigm has yet to be established. All three studies identified in this report were low-quality; therefore, findings need to be interpreted with caution. Future prospective, randomized studies need to be conducted in order to determine the optimal sequencing of treatment for these patients.